Market news
Two ophthalmic candidates will now head to their next clinical stages of development in dry eye and ocular pain, respectively.
AI is being talked about as though business has never encountered a technological shift before. And just like the other times, one thing gets overlooked.
Bausch & Lomb Corp (BLCO) reports impressive 8% revenue growth and 28% EBITDA increase, while addressing competitive challenges and strategic priorities.
Bausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook. The company said improved product mix, productivity initiatives and lower fixed-cost intensity suppor
Detailed price information for Bausch & Lomb Corp (BLCO-N) from The Globe and Mail including charting and trades.
Detailed price information for Bausch & Lomb Corp (BLCO-N) from The Globe and Mail including charting and trades.
Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a sustained-release GA implant.
Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.